Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada, Hiroshi Tada, Tsutomu Iwasa, Kei Koizumi, Tsuguo Iwatani, Yasuaki Sagara, Takashi Kuwayama, Masafumi Shimoda, Tatsunari Sasada, Koichiro Tsugawa, Yoshihiro Kawaguchi, Akihiko Shimomura, Takuhiro Yamaguchi, Hiroki Hasegawa, Shun Osaka, Satoshi Morita, Toshinari Yamashita

Open source

DOI: 10.1007/s10549-026-08004-5
Published: 2026-07
Container: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08004-5,
  title = {Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD},
  author = {Norikazu Masuda and Shigehira Saji and Yasuyuki Kojima and Masahiro Kitada and Hiroshi Tada and Tsutomu Iwasa and Kei Koizumi and Tsuguo Iwatani and Yasuaki Sagara and Takashi Kuwayama and Masafumi Shimoda and Tatsunari Sasada and Koichiro Tsugawa and Yoshihiro Kawaguchi and Akihiko Shimomura and Takuhiro Yamaguchi and Hiroki Hasegawa and Shun Osaka and Satoshi Morita and Toshinari Yamashita},
  year = {2026},
  journal = {Breast Cancer Research and Treatment},
  doi = {10.1007/s10549-026-08004-5},
  url = {https://doi.org/10.1007/s10549-026-08004-5}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
AU  - Norikazu Masuda
AU  - Shigehira Saji
AU  - Yasuyuki Kojima
AU  - Masahiro Kitada
AU  - Hiroshi Tada
AU  - Tsutomu Iwasa
AU  - Kei Koizumi
AU  - Tsuguo Iwatani
AU  - Yasuaki Sagara
AU  - Takashi Kuwayama
AU  - Masafumi Shimoda
AU  - Tatsunari Sasada
AU  - Koichiro Tsugawa
AU  - Yoshihiro Kawaguchi
AU  - Akihiko Shimomura
AU  - Takuhiro Yamaguchi
AU  - Hiroki Hasegawa
AU  - Shun Osaka
AU  - Satoshi Morita
AU  - Toshinari Yamashita
PY  - 2026
JO  - Breast Cancer Research and Treatment
DO  - 10.1007/s10549-026-08004-5
UR  - https://doi.org/10.1007/s10549-026-08004-5
ER  -

APA

Masuda, N., Saji, S., Kojima, Y., Kitada, M., Tada, H., Iwasa, T., Koizumi, K., Iwatani, T., Sagara, Y., Kuwayama, T., Shimoda, M., Sasada, T., Tsugawa, K., Kawaguchi, Y., Shimomura, A., Yamaguchi, T., Hasegawa, H., Osaka, S., Morita, S., & Yamashita, T. (2026). Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08004-5

Source records

crossref · retrieved 2026-09-27T01:10:41.832Z